Background: CHOP is accepted as the gold standard for first line chemotherapy of aggressive non-Hodgkin's lymphoma (NHL). A dose-escalation study of CHOP was conducted to determine the maximal tolerated dose (MTD) and toxicity profile of CHOP at three-week intervals with or without prophylactic recombinant human granulocyte colony-stimulating factor (rHuG-CSF) in patients with aggressive NHL.
Introduction
Although aggressive non-Hodgkin's lymphoma (NHL) is curable by combination cytotoxic chemotherapy, lymphoma recurs in a significant proportion of patients [1] . Several attempts have been made to improve the outcome of chemotherapy in patients with NHL, including the addition of other cytotoxic agents and greater dose intensification. Five randomized comparisons of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) with second-and third-generation regimens, however, failed to demonstrate a significant advantage of any treatment over CHOP with regard to complete remission or overall survival. In addition, the rate of severe toxicities with CHOP was lower than those of the second-and third-generation regimens [2] [3] [4] [5] [6] . As a result, CHOP is still accepted as the gold standard for first-line chemotherapy in aggressive NHL. One interpretation for these disappointing results might be that the addition of other myelosuppressive agents in secondand third-generation regimens induced a decrease in the dose intensities of doxorubicin and cyclophosphamide, considered to be the key drugs in chemotherapy against NHL [7] .
Recently, it has been reported that high-dose therapy with autologous stem cell rescue improved event-free and overall survival in patients with relapsed lymphoma [8] . Moreover, autologous bone marrow transplantation after myeloablative chemotherapy as a front-line chemotherapy was suggested to lead to promising outcomes in patients with high-intermediate risk and high-risk, according to the International Prognostic Index (IPI) [9, 10] . These results suggested that dose intensity of anticancer agents in the treatment of NHL is still an important factor.
Administration of granulocyte colony-stimulating factor (G-CSF) prevented neutropenic complications and, accordingly, enabled a decrease in treatment delay and dose reduction [11] . As doxorubicin and cyclophosphamide are myelosuppressive agents in CHOP regimen, the doses of these drugs can be escalated and the interval can be shortened when using G-CSF [12] [13] [14] [15] [16] .
From this background, dose escalation of doxorubicin and cyclophosphamide is considered a reasonable strategy for the development of a treatment for aggressive NHL. We have conducted a dose escalation study of CHOP in Japanese patients with aggressive NHL to determine the MTD and its toxicity profile. Although the primary endpoint of the present study was neither response nor survival, we also report here the results of follow-up on 33 patients treated in this protocol.
Patients and methods

Eligibility criteria
Eligibility criteria were as follows: patients with intermediate-and high-grade non-Hodgkin's lymphoma (NHL), according to the Working Formulation [17] ; clinical stage of II, III or IV, by the Ann Arbor system; aged 15-65 years; and a good performance status (PS 0-2) by the Eastern Cooperative Oncology Group (ECOG) criteria. Patients whose lymphoma had been treated with radiotherapy alone were eligible for the study, but prior chemotherapy was not allowed. Patients with lymphoma involving the central nervous system were ineligible. Patients with mycosis fungoides, Sezary's syndrome, adult T-cell leukemia/lymphoma and lymphoblastic lymphoma were excluded. Patients with diabetes mellitus requiring insulin therapy were ineligible.
Other eligibility criteria included neutrophil count ^ 1500/ul, platelet count > 100,000/ul, aspartate amino-transferase (AST) and alanine amino-transferase (ALT) levels $2.0 times the upper limit of the normal range, BUN and serum creatinine level within the normal limit, PaO 2 level >70 mmHg and normal cardiac left ventricular ejection fraction (>50%). Pre-treatment staging procedures included a physical examination, complete blood cell counts with differential and platelet counts, biochemical examination, bone marrow aspiration and biopsy, chest X-ray, computed tomography scanning of the chest and abdomen, and gallium scincigraphy. Written informed consent was obtained from all patients. The institutional review board of the National Cancer Center of Japan approved the protocol.
Treatment
All patients were treated while hospitalized until the second cycle was completed. The dose escalation schedule is shown in Table 1 . Starting from the standard CHOP regimen, consisting of cyclophosphamide 750 mg/m 2 intravenously (i.v.) day 1, doxorubicin 50 mg/m 2 i.v. day 1, vincristine 1.4 mg/m 2 (maximum 2 mg) i.v. day 1, and prednisolone 100 mg by mouth for five days, dose escalation was conducted in cohorts of three consecutive patients per dose level. The cyclophosphamide dose was increased by 250 mg/m 2 to 2250 mg/m 2 and the dose of doxorubicin was escalated from 50 mg/m 2 to 70 mg/m 2 , while the doses of vincristine and prednisolone were fixed. Prednisolone was omitted in a patient who was suspected to be a hepatitis-virus carrier, indicated by positive results for HBs antigen or hepatitis C virus (HCV) antibody. The complete blood cell counts and blood chemistry were monitored at least three times per week and every week, respectively, until the second cycle was completed.
Toxicity was evaluated according to the Japan Clinical Oncology Group-Common Toxicity Criteria (CTC), an expanded version of the National Cancer Institute-CTC from the US [18] . Dose-limiting toxicity was determined by evaluation after the first cycle of therapy, and was defined as grade 4 neutropenia for three days or more, grade 4 neutropenia accompanied by fever (> 38 °C) for three days, grade 4 thrombocytopenia, or any grade 3 or higher non-hematological toxicity, except anemia, alopecia, anorexia, vomiting, or general malaise. If dose limiting toxicities occurred in one of three patients at a specific dose level in the first cycle, three additional patients were treated at that dose level. The maximal tolerated dose (MTD) was defined as the dose level at which two of six patients developed dose limiting toxicities in the first cycle. To determine the MTD without prophylactic use of recombinant human granulocyte-colony stimulating factor (rHuG-CSF), rHuG-CSF was administered after neutrophil counts of less than 500/jal for three days were observed and until recovered to 5000/ul. After the MTD was determined without the prophylactic use of rHuG-CSF, dose escalation was continued with prophylactic use of rHuG-CSF, which was administered subcutaneously at a dose of 2.0 ug/kg/day from day 3 until day 15. To equalise the total dose of doxorubicin administered, the treatment was repeated every three weeks for eight cycles at levels 1 and 2 (a total planned dose of doxorubicin of 400 mg/m 2 ), seven cycles at levels 3 and 4 (a total planned dose of doxorubicin of 420 mg/m 2 ) and six cycles at level 5-10 (a total planned dose of doxorubicin of 420 mg/m 2 ) after the patient fulfilled the following criteria; neutrophil count > 1000/ul, platelet count ^100,000/ul, creatinine level within the normal limit, grade 1 or less for any non-hematological toxicity except alopecia. If the patient responded to the treatment but dose limiting toxicities were observed, doses of cyclophosphamide and doxorubicin were reduced to 75% for the subsequent cycles. If there was liver toxicity with a total bilirubin level of more than 1.2 mg/dl at the time of administration, the dose of doxorubicin was reduced to 50%. Once patients had a temperature > 38 °C, they were treated with broad-spectrum antibiotics after blood culture for a bacteriological survey. Antiemetic prophylaxis with granisetron was used. Daily oral trimethoprim/sulfamethoxazole was used for the prevention of pneumocystis carinii pneumonitis. To determine cardiotoxicity, the left ventricular ejection fraction was observed before enrolment and after the completion of the treatment. Relative dose intensity of doxorubicin and cyclophosphamide per week was calculated by dividing the administered dose at each level by the dose of standard CHOP dosage for each drug. Radiation therapy was added after completion of the dose-escalated CHOP for bulky lesions, defined as any mass ^ 10 cm in diameter, or a mediastinal mass ^ one-third the chest diameter.
Patients were evaluated for antitumor response to the doseescalated CHOP. Complete response (CR) was defined as the disappearance of all measurable or assessable disease and all signs and symptoms of disease for at least four weeks. Partial response was defined as a reduction of 50% or greater in the sum of the products of the perpendicular diameters of all measurable lesions and the appearance of no new lesions for at least four weeks. Progressive disease (PD) was defined as an increase of 25% in the size of any lesion or development of any new lesions. Relapse was defined as an increase of 25% in the size of any lesion or development of any new lesions in CR patients.
Patients were classified as low/low-intermediate risk or high-intermediate/high risk, according to the International Prognostic Index (IPI) for analysis [10] , Overall survival was calculated from the initial day of chemotherapy until death or the date of the last follow-up, or until the date of relapse in the case of progression-free time. Overall survival and progression-free survival duration curves were plotted according to the Kaplan-Meier method.
Results
Between December 1993 and June 1996, a total of 34 patients with NHL were enrolled into the study. One patient with clinical stage IV NHL who was treated with the standard CHOP (level 1) was excluded from the study because of histopathology of follicular mixed type. The remaining 33 patients were evaluable for toxicity and response. The characteristics of the 33 patients are shown in Table 2 . Bone marrow involvement was seen in Table 2 . Patient characteristics (n = 33). 26 (79) 7 (21) 22 (67) 11 (33) 4 (12) 2 (6) 5 (15) 21 (64) 1 (3) 10(30) 24 (73) 5 (15) 4 (12) 6 (18) 3 (9) 24 (73) 12 (36) 14 (42) 7 (21) 4 (12) 9 (27) 9 (27) 9 (27) 
Hematological toxicity
Hematological toxicities in the first cycle are shown in Table 3 ; the predominant toxicity was neutropenia. Neither grade 4 thrombocytopenia nor grade 3 anemia was observed in the first cycle. At level 5, two out of four patients experienced grade 4 neutropenia in the first cycle for three days and five days, respectively. Therefore, dose level 5, consisting of doxorubicin 70 mg/m 2 and cyclophosphamide 1250 mg/m 2 in combination with the standard dose of vincristine and oral prednisolone, was determined as the maximal tolerated dose without prophylactic use of rHuG-CSF. Then, the dose Table 4 . At level 9, two patients experienced grade 4 neutropenia for three and four days, respectively, in the fifth cycle. Although the incidence of dose limiting toxicity in the first cycle at level 10, which was one out of six patients, did not fulfil the definition of MTD in the original protocol, further dose escalation was stopped because three out of six patients at level 10 experienced dose-limiting toxicities in the second and subsequent cycles. Therefore, we concluded that level 10 was approximately the MTD with prophylactic rHuG-CSF. Ten patients experienced grade 3 anemia in the subsequent sixteen cycles. Packed red-cell transfusion was required in two patients at level 3, three at level 5, one at level 6 and one at level 9 during all cycles. Platelet transfusion was required in one patient at dose level 10.
Non-hematological toxicity
Non-hematological toxicities such as nausea and vomiting were mild. All patients developed alopecia, which was generally complete. Grade 3 or higher non-hematological toxicities were not observed in the first cycle. Grade 3 and higher non-hematological toxicities of all cycles are shown in Table 4 . Transient grade 3 elevated liver enzymes accompanied by intravascular coagulation syndrome was observed in one patient at level 2 in the third cycle and transient grade 3 elevated liver enzymes in one patient at level 6 in the second cycle. One patient was positive for anti-hepatitis C virus (HCV) antibody, detected at dose level 4. The patient experienced grade 4 pancytopenia, infection, and elevated liver enzymes after five cycles of chemotherapy. In spite of intensive supportive care, the patient died of hepatic failure. Autopsy was not permitted in this patient but there were no symptoms or laboratory findings suggesting relapse of the NHL. Subsequently, anti-HCV-positive patients were excluded from the study. In no patient did the left ventricular ejection fraction (LVEF) decrease more than 20% from the base line, with the exception of two patients whose LVEF decreased from 82% to 62% at level 2 and from 65% to 48% at level 10, respectively. No congestive heart failure was observed. Grade 2 or higher hemorrhagic cystitis and/or neurotoxicities were not observed. Four patients suffered from herpes virus activation during the protocol treatment.
It was noted that one patient at level 9 developed acute myeloblastic leukemia (AML) 3.5 years after the completion of the dose-escalated CHOP. Karyotypic analysis of bone marrow aspiration at the diagnosis of leukemia showed 47, XX, +add(8)(q24), add(12)(ql3), t(16;2I)(q24;q22) in 19 of 20 cells. Although bone marrow findings in the patient indicated a complete remission with normal karyotype following treatment with idarubicin and cytarabine, the patient relapsed after remission of five months and died two months thereafter of AML progression.
Dose reductions and treatment delays
Doses were reduced in 25 cycles for 9 patients (12% of total cycles administered). Treatment delays were ob- served in 33 cycles for 17 patients (15% of total cycles administered) mainly because of neutropenia. One patient at level 3 received an additional cycle of standard CHOP after seven cycles of the study protocol, and one patient at level 4 received radiotherapy for a residual lesion omitting the seventh cycle, at the discretion of the attending physician. Two patients with high-intermediate/high risk at level 5 received an additional cycle of dose-escalated CHOP after six cycles of the study protocol study were completed.
Response and the relative dose intensity
The response and the relative dose intensities of doxorubicin and cyclophosphamide are listed in Table 5 . The median relative dose intensity of doxorubicin and cyclophosphamide at level 10 in comparison to the standard CHOP regimen reached 1.38 and 2.95, respectively. Complete remission (CR) was achieved in 10 out of 15 patients (67%) without prophylactic use of rHuG-CSF and in 15 out of 18 patients (83%) with prophylactic rHuG-CSF (P = 0.27). Partial remission was seen in the remaining eight patients and the overall response rate was 100% (76% CR and 24% PR). With regard to the international prognostic factors, CR was observed in 18 of 22 patients with low/low-intermediate risk (82%) and in 7 of 11 patients with high-intermediate/high risk (64%) (P = 0.25). Radiation therapy after dose-escalated CHOP was performed for bulky lesions in four patients and for residual lesions in three patients. NHL relapsed in 16 patients and 4 of them had central nervous system (CNS) involvement as an initial relapse site; the median interval from the initial day of dose-escalated CHOP was 13 months. Among these patients with CNS relapse, one patient who received radiotherapy for CNS disease maintained a complete remission four years after the radiotherapy. One patient at level 5 in complete remission was lost to follow-up and the median follow-up duration of surviving patients was 5.0 years (range 1.5-5.9 years). Progression-free survival and overall survival are shown in Figures 1 and 2 . Progression-free survival rate at five years was 45% (48% in low/low-intermediate risk and 27% in high-intermediate/high risk by IPI; P = 0.57). Overall survival rate at five years was 66% (72% in low/ low-intermediate risk and 55% in high-intermediate/ high risk by IPI; P = 0.18). Ten patients died, one from hepatic failure, one from AML progression, and eight from lymphoma progression. Discussion CHOP remains the gold standard for the first-line chemotherapy in aggressive NHL, based on the results of randomised trials [2] [3] [4] [5] [6] ; however, the therapeutic efficacy of CHOP is still inadequate, particularly in high-intermediate/high risk patients with long-term survival rates of only 26% to 43% [10] . Although some retrospective studies in NHL have suggested that response and survival rates might be related to relative dose intensity of chemotherapy [7, [19] [20] [21] , direct comparison of dose intensity among chemotherapeutic regimens containing different drugs is difficult. If the dose intensity of key drugs is an important issue in the therapeutic outcome in NHL, dose escalation of doxorubicin and cyclophosphamide should be a reasonable strategy.
In the present study, a significant dose escalation of doxorubicin and cyclophosphamide with conventional doses of vincristine and prednisolone was feasible with prophylactic use of rHuG-CSF. Similar dose escalation studies of CHOP have been published [12, 13] . Shipp et al. reported encouraging results of high-dose CHOP, consisting of doxorubicin 70 mg/m 2 and cyclophosphamide 4 g/m 2 , in which the rate of complete remission was 86% and 79% of these patients remained progressionfree. Nevertheless, the follow-up period was short and many complications were observed, including febrile neutropenia in 65% of treatment cycles, and platelet transfusion was required in 84% of patients [12, 22] . Another study on dose escalation of CHOP, recently published by Santoro et al., used a similar strategy to the present study [13] . The MTD of the dose-escalated CHOP in that study was 75 mg/m 2 doxorubicin in combination with cyclophosphamide at 1750 mg/m 2 without G-CSF and 2750 mg/m 2 with G-CSF, which are a little higher than the MTD in the present study. The difference, however, may be the result of a different criterion for dose limiting toxicity, that is, the duration of grade 4 neutropenia lasting seven days in that study, in comparison with those lasting three days in the present study. The MTD might be also affected by the dose of G-CSF at 5 ug/kg in that study compared with those at 2 ug/kg in the present study. Also, the MTD with prophylactic G-CSF in the present study was not based on the dose limiting toxicities of the first cycle as defined in the original protocol, but on those of all cycles. Similarly, other trials have attempted to increase dose intensity. Gordon et al. reported that the dose of ProMACE-CytaBOM regimen could be safely increased to 200%, with the use of GM-CSF [23] . Talbot et al. also conducted a dose escalation study of epirubicin and cyclophosphamide, and defined the MTD of epirubicin at 150 mg/m 2 and of cyclophosphamide at 1500 mg/m 2 , double the standard doses [24] .
Another strategy that has been used to increase dose intensity is shortening the interval of chemotherapy. Tanosaki et al. reported that the dose of cyclophosphamide 1500 mg/m 2 in biweekly CHOP could be repeated with G-CSF support [14] . Furthermore, Trumper et al. demonstrated that significant dose escalation of CHOP with etoposide (CHOEP) was feasible at biweekly intervals without stem-cell rescue [15, 16] . These results suggested that the dose intensification of regimens is feasible with appropriate administration of hematopoietic growth factors.
However, it is unknown whether these dose-intensified regimens are superior to the standard CHOP with regard to disease free or overall survival. The only prospective randomized trial by Meyer et al. could not demonstrate any role of dose-intensification of BACOP on the response rate and overall survival of patients with NHL [25] . In that study, however, the dose-intensity of doxorubicin in the escalated BACOP arm was only 30% greater than that in the standard BACOP arm. Moreover, the dose of cyclophosphamide was not escalated. In the present study, the doses of doxorubicin and cyclophosphamide were increased to 138% and 295% of the standard CHOP dosages, respectively, and the doseescalated CHOP in the present study was reasonably well tolerated. Although the response and survival rates in the present study were comparable to those of the standard CHOP [2] [3] [4] [5] [6] , this was a phase I study and a small number of patients were treated. It should be noted that four of six patients treated at level 10 had high/intermediate risk, by age-adjusted IPI [10] , and two of four patients relapsed with CNS involvement. The clinical benefit of the dose-escalated CHOP should be evaluated in a larger, prospective, randomised trial.
Although the extraordinary frequency might be a regional characteristic or the result of some selection artifact, 20 patients (61%) in the present study had bone marrow involvement, which might be a potential risk factors for central nervous system involvement [26] and 4 of 16 relapsed patients had central nervous system involvement as the initial relapse site. Relapse in the central nervous system means a poor prognosis in NHL and only a small percentage of patients might be curable with high-dose therapy with stem-cell rescue [27] . Prophylaxis for central nervous system involvement might be needed in dose-escalated CHOP.
It has been reported that the risk of acute non-lymphocytic leukemia associated with cyclophosphamide was small [28] ; however, dose-escalation of cyclophosphamide possibly increases the risk of secondary leukemogenesis [29] . In a high-dose CHOP study by Shipp et al., one patient developed myelodysplasia with an Ilq23 chromosome abnormality five months after the completion of therapy [12] . Unfortunately, one patient in the present study also developed acute myeloblastic leukemia 3.5 years after the completion of the dose-escalated CHOP. The causal relationship between dose-escalated CHOP and acute myeloblastic leukemia is unclear in this patient because the patient received many salvage chemotherapeutic regimens after the relapse of NHL until the development of leukemia.
Finally, one patient who was positive for anti-HCV antibodies unexpectedly died of hepatic failure. Although it has been reported that severe hepatic dysfunction was uncommon in HCV-positive patients receiving intermittent chemotherapy [30] , two cases with HCV who developed fulminant liver failure after chemotherapy have been reported [31] . Accordingly, careful consideration should be given to conducting chemotherapy in patients with HCV.
In conclusion, dose escalation of doxorubicin and cyclophosphamide was feasible and resulted in a significant increase in dose-intensity compared to standard CHOP. The recommended dose of dose-escalated CHOP with prophylactic use of rHuG-CSF is doxorubicin at 70 mg/m 2 and cyclophosphamide at 2250 mg/m 2 . Although the treatment failure rate at level 10 was high, there may have been selection bias in patient enrollment, because the present study was in a phase I setting. The Japan Clinical Oncology Group conducted a randomized phase II study comparing the dose-escalated CHOP to biweekly CHOP with standard doses [32] . A similar study is currently being conducted by European study group [16] . A prospective, randomized phase III study comparing these dose-intensified CHOP regimens to the standard CHOP is necessary to determine whether doseintensified CHOP can improve disease-free and overall survival in patients with NHL.
